Alpha Cognition IncCanadian Securities Exchange:ACOGView on NASDAQ
- LAST PRICE8.1100
- TODAY'S CHANGE (%)0.0600 (0.7453%)
- Bid / Lots7.7000/ 10
- Ask / Lots8.5000/ 20
- Open / Previous Close8.1100 / 8.0500
- Day Range
- 52 Week Range
- Volume100
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ACOG |
|---|
Nov 15, 2024
Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update, from 5:00PM ET on Friday Nov 15, 2024 by Dow Jones
5:00PM ET on Friday Nov 15, 2024 by Dow JonesPress Release: Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update, from 5:00PM ET on Friday Nov 15, 2024 by Dow Jones
5:00PM ET on Friday Nov 15, 2024 by Dow Jones
Nov 12, 2024
Alpha Cognition Announces Pricing of $50 Million Upsized Public Offering and Nasdaq Listing, from 9:22AM ET on Tuesday Nov 12, 2024 by Dow Jones
9:22AM ET on Tuesday Nov 12, 2024 by Dow Jones
Oct 31, 2024
Alpha Cognition Announces Proposed Financing and Share Consolidation in connection with Nasdaq Uplisting, from 8:30AM ET on Thursday Oct 31, 2024 by Dow Jones
8:30AM ET on Thursday Oct 31, 2024 by Dow Jones
Oct 21, 2024
*DJ Alpha Cognition Says Henry Du Appointed Interim CFO, VP Finance and Accounting >ACOG.L, from 8:31AM ET on Monday Oct 21, 2024 by Dow Jones
8:31AM ET on Monday Oct 21, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Alpha Cognition Inc | 48.6M | -1.7x | --- |
Nurexone Biologic Inc | 46.6M | -5.9x | --- |
ZYUS Life Sciences Corp | 59.5M | -1.3x | --- |
Biomind Labs Inc | 39.5M | -34.7x | --- |
Briacell Therapeutics Corp | 29.7M | -1.9x | --- |
Satellos Bioscience Inc | 96.4M | -4.0x | --- |
Company Information
Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062 is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. It is in preclinical development for the treatment of ALS.
Contact Information
- Headquarters
- c/o 1200 - 750 West Pender StreetVancouver, BC, Canada V6C 2T8
- Phone
- 604-564-9244
- Fax
- ---
Executives
- Independent Chairman of the Board
- Len Mertz
- Chief Executive Officer, Director
- Michael Mcfadden
- Interim Chief Financial Officer, Vice President - Finance and Accounting
- Henry Du
- Chief Operating Officer
- Lauren D'Angelo
- Corporate Secretary, Director
- Kenneth Cawkell
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $48.6M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 6.0M |
Alpha Cognition Inc does not pay a dividend. | |
Beta | 3.01 |
EPS | $-4.78 |
Book Value | $-1.40 |
P/E Ratio | -1.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
